Trial · NCT04521920
Providing Suboxone and PrEP Using Telemedicine
NCT04521920, Not applicable, Completed, Duke University; results first posted 2023-06-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Providing Suboxone and PrEP Using Telemedicine. Trials, record NCT04521920. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04521920
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Providing Suboxone and PrEP Using Telemedicine
- NCT number
- NCT04521920
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 17 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Opioid Use, Opioid-use Disorder, Risk Reduction, Hiv
- Interventions
- Suboxone, PrEP
- First posted
- 2020-08-21
- Last updated
- 2023-06-09
- Results first posted
- 2023-06-08
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Demonstrate no or Minimal Opioid Use at 3 Months | 3 months | Defined as self-reported opioid use in prior month |
| Primary | Number of Participants Who Demonstrate no or Minimal Opioid Use at 6 Months | 6 months | Defined as self-reported opioid use in prior month. |
| Primary | Number of Participants Who Remain HIV Negative at 3 Months | 3 months | Measured via negative HIV test. |
| Primary | Number of Participants Who Remain HIV Negative at 6 Months | 6 months | Measured via negative HIV test. |
| Primary | Persistence in Care at 3 Months | 3 months | Defined as the number of participants who remain on treatment (MOUD or PrEP). |
| Primary | Persistence in Care at 6 Months | 6 months | Defined as the number of participants who remain on treatment (MOUD or PrEP). |
| Other | Motivators and Barriers Affecting Medication Adherence and Persistence | 6 month | Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method) |
| Other | Motivators and Barriers Affecting Program Persistence | 6 month | Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method) |
| Other | Participant Perceived Usefulness of the Program | 6 month | Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method) |
| Other | Participant Perceived Usefulness of the Program | 1 month | Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant (qualitative method) |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Demonstrate no or Minimal Opioid Use at 3 Months | 3 months | Data not collected on 8 participants. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Demonstrate no or Minimal Opioid Use at 6 Months | 6 months | Data not collected on 11 participants. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Remain HIV Negative at 3 Months | 3 months | Received labs to confirm HIV status from 8 participants at month 3. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Remain HIV Negative at 6 Months | 6 months | Received labs to confirm HIV status from 3 participants at month 6 | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Persistence in Care at 3 Months | 3 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Persistence in Care at 6 Months | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Motivators and Barriers Affecting Medication Adherence and Persistence | 6 month | |||
| OTHER_PRE_SPECIFIED | Motivators and Barriers Affecting Program Persistence | 6 month | |||
| OTHER_PRE_SPECIFIED | Participant Perceived Usefulness of the Program | 6 month | |||
| OTHER_PRE_SPECIFIED | Participant Perceived Usefulness of the Program | 1 month |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 outcomesResults by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Demonstrate no or Minimal Opioid Use at 3 Months | Medication and Telemedicine Follow up | 6 | Participants | ||
| Number of Participants Who Demonstrate no or Minimal Opioid Use at 6 Months | Medication and Telemedicine Follow up | 5 | Participants | ||
| Number of Participants Who Remain HIV Negative at 3 Months | Medication and Telemedicine Follow up | 8 | Participants | ||
| Number of Participants Who Remain HIV Negative at 6 Months | Medication and Telemedicine Follow up | 3 | Participants | ||
| Persistence in Care at 3 Months | Medication and Telemedicine Follow up | 13 | Participants | ||
| Persistence in Care at 6 Months | Medication and Telemedicine Follow up | 12 | Participants |
Source ClinicalTrials.gov
Participant flow4
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Medication and Telemedicine Follow up | 17 | |
| Overall Study | Month 3 | Medication and Telemedicine Follow up | 13 | |
| Overall Study | COMPLETED | Medication and Telemedicine Follow up | 12 | |
| Overall Study | NOT COMPLETED | Medication and Telemedicine Follow up | 5 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Medication and Telemedicine Follow up | 0 | 17 |
| Total, other adverse events | Medication and Telemedicine Follow up | 0 | 17 |
| Total, serious adverse events | Medication and Telemedicine Follow up | 0 | 17 |
Source ClinicalTrials.gov
Papers17
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04521920
GET https://conductscience.org/api/trials/v1/NCT04521920/registered